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PCN10
RelatioNshiP BetweeN PRogRessioN-FRee suRvival (PFs) aNd oveRall 
suRvival (os) iN hoRmoNe ReCePtoR-Negative metastatiC BReast 
CaNCeR (mBC): a ComPaRative eFFeCtiveNess aNalysis usiNg liNked 
Claims, emR, aNd moRtality ReCoRds
Schabert V.F.1, Chen Y.J.1, Sun K.2, Wang Y.2
1IMS Health, Alexandria, VA, USA, 2IMS Health, Plymouth Meeting, PA, USA
Objectives: FDA accelerated approvals for some chemotherapies used PFS as an OS 
surrogate. However, one mBC approval was revoked after OS gains were not observed 
post-approval. We compared PFS with OS by first-line (1L) chemotherapy using 
real world evidence from US mBC patients. MethOds: IMS Health Comprehensive 
Disease Records for Breast Cancer link IMS PharMetrics Plus, oncology EMRs, and 
Social Security Death Index. Female breast cancer patients (ICD-9-CM 174.x, 233.0) 
were selected with index metastasis (ICD-9-CM 196.x-198.x or EMR Stage IV) 
7/1/2006-3/31/2012, age ≥ 18, no HR overexpression, 1L chemotherapy (anthracy-
clines or txanes [AT] or new cytotoxic agents [NCA]), enrollment 180 days pre-index 
and ≥ 30 days post-index, and no other malignancies. PFS proxy was 1L duration; 
OS was measured until death or censoring (end of enrollment). Log-rank analysis 
compared PFS by 1L treatment. A Cox proportional hazards model assessed post-1L 
OS by 1L chemotherapy and duration, propensity for NCA vs. AT, HER2 status, and 
patient characteristics. Results: Of 845 mBC patients, 334 met study criteria (mean 
[SD] age= 51.7 [8.7] years, 20.4% HER2+). Propensity for NCA (n= 70) vs. AT (n= 264) 
increased with diabetes history (OR= 2.79, 95% CI 1.12-6.90) and higher pre-index 
health care expenditures (OR= 1.27, 95% CI 1.05-1.54). 1L NCAs were administered 
a mean (median) 195.2 (73.0) days (anthracyclines 53.5 [44.0], taxanes 122.2 [47.5], 
-2Log LR 54.3, 2 df, p< .0001). Cox regression estimated that 30 additional days of 
1L chemotherapy predicted slightly shorter post-1L OS (HR= 1.03, 95% CI 1.00-1.06); 
NCA (vs. AT) predicted stronger decreases in post-1L OS (HR= 2.32, 95% CI 1.11-4.86) 
despite propensity adjustment. cOnclusiOns: Duration of 1L chemotherapy, as 
a proxy for PFS, predicted slightly shorter post-1L OS. Choice of 1L chemotherapy 
was a stronger predictor of post-1L OS, adjusted for selection bias. Real world data 
suggests that PFS is a poor OS surrogate in mBC.
PCN11
magNitude oF BeNeFit aNd Costs FoR ReCeNt solid tumoR ageNts
Binder G.1, Milentijevic D.2, Squier M.1, Whiting S.1, Brown G., Renschler M.F.1
1Celgene Corporation, Summit, NJ, USA, 2Market Access Solutions, Raritan, NJ, USA
Objectives: Phase 3 oncology clinical trials have had success rates of 41% 
(Djulbegovic, Arch Int Med 2008). Against this backdrop, context is needed on the 
magnitude of benefit to expect from future successful trials, and the interplay of 
cost. Recognizing the limitations of comparing results across trials and therapies, we 
assessed recent FDA solid tumor approvals showing overall survival (OS) benefit in a 
randomized trial. The objective of this analysis is to define the magnitude of benefit 
and cost of solid tumor therapies approved by FDA from 2009-2013 having phase 3 OS 
benefit. MethOds: A systematic review of CenterWatch FDA-Approved Drugs and 
FDA sNDA/sBLA databases was conducted. Inclusion criteria required FDA approval 
or efficacy supplement, with OS data published 2009-2013. Hazard ratio (HR) and 
absolute and relative gain in median OS were assessed. First month drug costs were 
determined for 4Q2013, using methods previously described by Bach (NEJM 2009). 
Agents intended to be administered for £ 6 weeks were excluded from the cost 
analysis. Limitations include omission of many agents that represent important 
advances yet did not demonstrate statistically significant OS benefit relative to a 
control arm. Results: 18 FDA approved agents across 25 indications for 9 tumor 
types were assessed. The mean HR (range) and the mean relative gain in median OS 
vs trial comparator was 0.702 (0.410-0.817) and 27.91% (11.9%-67.2%), respectively. 
Medians for each measure were 0.725 and 23.6%. Mean first month treatment costs 
were $12,601 ($5,881-$50,025) with median costs of $9,282. cOnclusiOns: Over the 
last 5 years, for FDA-approved agents for treatment of solid tumors, the magnitude 
of survival benefit, measured either as Hazard Ratio or relative gain in median OS, 
was 24-30%. This benefit, and first month costs of $9 - 13,000, may represent mid-
points of expected levels for future solid tumor agents.
PCN12
tReatmeNt PatteRNs aNd outComes iN metastatiC ColoReCtal 
CaNCeR (mCRC) PatieNts tReated iN a CommuNity oNCology settiNg
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Objectives: To describe and characterize mCRC patients who received 3rd-line 
therapy and to investigate the association of patient outcomes and treatment pat-
terns in a real-world community oncology network. MethOds: This retrospective 
study utilized data from the iKnowMed™ database and billing claims. Eligibility cri-
teria included diagnosis of mCRC, initiation of 1st-line therapy between 1/1/2007 and 
6/30/2011, and initiation of 3rd-line therapy (defined as index date) before 6/30/2012. 
The key outcome was overall survival (OS). Kaplan-Meier and Cox proportional 
hazard models were used to characterize the distribution and predictors of out-
comes. Results: 757 patients were eligible for the study. The most common 3rd-line 
therapies were anti-EGFR-based (55.4%), oxaliplatin-based (13.6%), and capecitabine-
based (11.4%). OS was 8.0 (95% CI: 7.1-8.9), 8.8 (7.4-11.0), and 9.1 (6.9-11.2) months, 
respectively. Over half of patients were ≤ 65 years old (54.3%), male (55.2%), treated in 
the Southern region (61.8%), overweight/obese (56.6%), and the majority had an ECOG 
performance status ≤ 1 (78.7%). 51.8% of patients had prior comorbidities. The 5 most 
common comorbidities were hematologic, cardiovascular, gastrointestinal, neuro-
logic, and endocrine disease. KRAS testing rates at index date were 35.4% (wild-type 
26.3%, mutation 9.1%). Of KRASwild-type patients, 80.9% were treated with anti-EGFR-
based regimens which was consistent with NCCN recommendations. cOnclusiOns: 
This comparative effectiveness study in a real-world community setting shows that 
PCN7
aN aNalysis oF BiomaRkeR testiNg aNd aPPRoPRiate tReatmeNt amoNg 
womeN with BReast CaNCeR usiNg oNCology emR data
Foley K.1, Bizier R.1, Hansen L.G.2
1Truven Health Analytics, Cambridge, MA, USA, 2Truven Health Analytics, Northwood, NH, USA
Objectives: Personalized treatment for biomarker-specific breast cancer is a real-
ity. However, outcomes research has lagged behind due to lack of data sources 
capturing testing, results, and drug treatment. This study uses a new oncology elec-
tronic medical record (EMR) database to examine testing, documentation of results, 
and appropriate treatment among a cohort of women with breast cancer treated 
in community oncology practices. MethOds: The Truven Health MarketScan® 
Oncology EMR Database was used to select patients diagnosed with breast cancer 
between July 1, 2011 and September 30, 2013 who had at least 2 visits and known 
disease stage. Biomarker tests and results for estrogen receptor (ER), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) were observed 
along with patients’ drug treatment. Results: 57,660 women met inclusion cri-
teria. Documented biomarker testing varied by disease stage and test. ER testing 
was > 90% for women with stage I or II; 77% for stage IV patients. More than 86% 
of women with stage 0-III and 71% with stage IV had a PR test. HER2 testing was 
documented in 66% with stage 0, 77% with stage I-III, and 63% with stage IV. Overall, 
74%, 55%, and 2% of women who were ER positive, HER2 positive, and HER2 nega-
tive respectively received biomarker specific treatment. Treatment rates varied by 
disease stage, with > 80% of stage IV women receiving appropriate treatment for ER 
positive or HER2 positive cancer. Among HER2 negative stage IV women, appropri-
ate treatment was 16%. 6%, 12%, and 14% of patients respectively had a biomarker 
result that was not consistent with ER positive, HER2 positive, and HER2 negative 
treatment received. cOnclusiOns: Documentation of appropriate testing varied 
both by the type of test and disease stage. Quality improvement programs aimed 
at documentation as well as appropriate treatment may benefit patients treated in 
community oncology practice.
PCN8
is dePRessioN Related to uNdeRuse oF BReast CaNCeR sCReeNiNg?
Park C., Ma X., Lawson K.A.
The University of Texas at Austin, Austin, TX, USA
Objectives: Many studies have demonstrated that depression is associated with 
poor adherence to treatment of various diseases. Previous research has shown 
inconsistent results regarding the impact of depression on mammography use 
behaviors. The objective of this study was to assess the relationship between 
women’s depression and mammography use. To MethOds: This cross-sectional 
study used data from the 2012 Behavioral Risk Factor Surveillance System (BRFSS) 
and employed the Health Belief Model (HBM). The independent variable was the 
presence of depression. The dependent variable was mammogram use, which was 
defined based on the U.S. Preventive Services Task Force’s mammogram guidelines, 
categorized at three levels: 1) had never been screened, 2) had been screened, but not 
within two years, and 3) had been screened within two years. Multivariate ordinal 
logistic regressions were used for analyses. Results: An estimated population 
size of 45,578,030 women was included. Among this population, 23.02% of women 
reported the presence of a depressive disorder. A chi-square test showed a signifi-
cant relationship between mammogram use and depression (p< 0.001). The unad-
justed proportional odds ratio [95% CI] when comparing women with depression to 
women without depression on mammogram use was 0.81 [0.76, 0.86], which means 
that both the odds of ‘screened within two years’ versus the combined ‘screened, 
but not within two years’ and ‘never screened’ and the odds of combined ‘screened 
within two years’ and ‘screened, but not within two years’ versus ‘never screened’ 
were 0.81 times lower for women with depression when compared to women with-
out depression (p< 0.001). However, when demographic and HBM characteristics 
were held constant in the regression model, the adjusted proportional odds ratio 
[95% CI] (1.05 [0.97, 1.14]) was not significant (p= 0.197). cOnclusiOns: Depression 
itself was related to the underuse of mammography. However, after controlling 
for demographic and HBM characteristics, depression was not associated with the 
underuse of mammography.
PCN9
ComPlex sCReeNiNg test FoR eaRly CaNCeR diagNostiCs
Blavatska O.
Danylo Halytskyj Lviv National Medical University, Lviv, Ukraine
Objectives: Screening of colon, stomach, bladder, prostate cancers is very relevant 
to reduce mortality. The applicable diagnosis scheme doesn’t allow detecting tumor 
processes in the early stages, later diagnosis increases cost of the next treatment, 
reducing its effectiveness and declines the length and quality of life. MethOds: We 
proposed to improve diagnostics of colorectal and stomach cancer using one test; 
to apply the test for occult blood for urological field. Application of a combined test 
for determining hidden “high” and “low” bleeding in both fields displays this type 
of screening in a very interesting and economically appropriate rank. Rapid test 
for occult blood specific for human hemoglobin and transferrin is more sensitive, 
freely available in the pharmacy network, economically priced, easy to use and gives 
results on “cito”. Results: The first year results of the test use data are analyzed. 
Patients used tests purchased at their own expense. We’ve tested 88 patients for 
diagnosing possible colorectal and stomach cancer and 182 urological patients for 
diagnosing possible cancer of bladder and prostate. All 88 digestive patients test 
results for diagnosing possible colorectal and stomach cancer were negative; among 
182 tests of the urological patients we received 17 positive results, future diagnostics 
proved 7 Cr-cases and 1 with precancerous (is under control). Such data does not 
allow yet statistic analysis. cOnclusiOns: The project is under implementation. 
For 7 Cr-diagnosed patients the treatment allows almost twice increase of expected 
life time and the 8-th patient may become our first preventive Cr-case. Proved effi-
ciency of the screening algorithm would become a basis for changing the national 
standard of medical care in Lviv region and Ukraine in general.
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however, median overall survival (OS) analyses do not adequately capture this type 
of prolonged survival effect. Therefore, additional value metrics are necessary to 
completely describe ipilimumab’s survival impact in treatment-naïve metastatic 
melanoma patients vs other anti-cancer agents. MethOds: We conducted a lit-
erature review of trial data supporting approval of agents for various metastatic 
cancers within the last 10 years. Metrics included primary/secondary OS, median 
OS at approval, and Kaplan-Meier (KM) survival curves. Each agent was plotted, with 
x-axis reflecting total drug cost and y-axis reflecting improvement vs comparator 
for median and mean OS (area under KM curve), 1-year survival, and 1-year number 
needed to treat (NNT) to avoid 1 death. A line indicating an average cost-to-benefit 
ratio identified agents with highest relative value per metric. Ipilimumab (3-mg/
kg monotherapy) pooled phase II/III data from chemotherapy-naïve patients were 
assessed within this value metric portfolio. Results: Ipilimumab demonstrated 
high relative median OS improvement vs comparator (48.4% [0.3%–63.3% with other 
agents]), the greatest absolute and relative mean OS improvements (6.9 months 
[0.2–6.4 months with other agents]; 60.1% [1.3%–34.3% with other agents]), the great-
est relative 1-year survival improvement amongst first-line agents (41.9% [4.2%–
38% with other agents]), and the lowest NNT (5 patients [6–66 with other agents]). 
Ipilimumab’s high relative value was confirmed when plotting each drug’s clinical 
performance vs total drug costs. cOnclusiOns: Using relevant survival metrics, 
ipilimumab demonstrates high relative value within a value metric portfolio in 
metastatic diseases. Long-term survival data for other agents for metastatic cancers 
are not yet available to estimate ipilimumab’s long-term relative value.
PCN16
a ComPaRisoN oF toxiCity aNd suPPoRtive CaRe use BetweeN FouR 
CytotoxiC ageNts used iN the maNagemeNt oF metastatiC BReast 
CaNCeR (mBC))
Dranitsaris G.1, Knoth R.L.2, Cox D.2, Faria C.2
1Augmentium Pharma Consulting, Toronto, ON, Canada, 2Eisai, Inc., Woodcliff Lake, NJ, USA
Objectives: Capecitabine (C), gemcitabine (G) and vinorelbine (V) are commonly 
used as single agents in patients with MBC. Eribulin (E) is among the most recent 
cytotoxic agents to gain regulatory approval for MBC in the United States (U.S.) as 
a single agent. In this analysis, toxicity and supportive care use was compared 
between the four agents in a sample of MBC patients treated in a U.S. community 
oncology setting. MethOds: 411 patients (C= 144, G= 181, V= 96 and E= 90) who were 
treated in 19 community oncology clinics over the preceding two year period were 
identified. Data collection included baseline patient and disease characteristics, 
duration of therapy, supportive care, type of dose limiting toxicities and their impact 
on overall health care resource use. Results: The proportion of patients reporting 
at least one adverse event (any grade) with C, G, V and E was 45%, 65%, 75% and 63%. 
The most common toxicities with C, G and V were diarrhea (19.4%), anemia (34.6%) 
and neutropenia (50.0%). The most common toxicity for E was neutropenia (32.2%). 
Overall, 5.6%, 19.8%, 22.9% and 22.2% of patients receiving C, G, V and E required at 
least one medical intervention to manage a toxic event. Blood transfusions were 
most prevalent with G (12.3%) and V (13.5%). In contrast, unplanned clinic visits 
were most common with E (7.8%) and C (2.1%). Colony stimulating factor support 
was significantly higher with V (100%) relative to E (84.4%), G (72.9%) and C (63.9%) 
respectively (p < 0.01). However, toxicity was the cause of treatment discontinuation 
in significantly more patients receiving C (25.7%) compared to 8.6%, 11.5% and 8.9% 
of G, V and E patients (p < 0.05). cOnclusiOns: Significantly more patients receiv-
ing V required support with high cost colony stimulating factors. Capecitabine had 
less neutropenia and anemia, but more treatment discontinuations due to toxicity.
PCN17
RoBot-assisted veRsus CoNveNtioNal laPaRosCoPiC suRgeRy FoR 
ReCtal CaNCeR: a systematiC Review
Kim J., Lee S.H., Lim S., Lee N.R.
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
Objectives: The aim of this systematic literature review is to evaluate the safety 
and effectiveness of robot-assisted surgery (RAS) and conventional laparoscopic 
rectal surgery (CLS) for rectal cancer. MethOds: We performed a systematic review 
of available literature. Three international databases (OvidMedline, Ovid EMBASE, 
Cochrane Central Rgister of Controlled Trials) and six Korean databases were used 
in searching for existing literature. The PICO and the search strategy were deter-
mined through consultation with a methodologist and a clinician. 1,664 studies 
were found at first. The final selection was made after removing duplicates and 
applying the inclusion and exclusion criteria established beforehand. The Cochrane 
Risk of Bias (RoB) was used for randomized clinical trial and the Methodological 
index for non-randomized (MINORS) for observational (cohort and case-control) 
studies were utilized for evaluating the quality of literature. Results: 15 two-arms 
studies involving 1,876 patients were finally included. RAS was associated with a 
lower rate of intraoperative conversion than CLS (RR= 0.29, 95% CI= 0.15-0.56). The 
operating time was higher for RAS (MD= 43.14, 95% CI= 18.25-68.02, I2= 95%), but only 
the directional nature could be determined due to the heterogeneity of literature. 
The RAS had a higher number of lymph node extraction (MD= 0.88, 95% CI= 0.00-
1.75) and the time to first flatus was short (MD= 0.14, 95% CI= -0.28-0.00). However, 
this difference does not indicate a significant clinical difference. cOnclusiOns: 
RAS was associated with a lower intraoperative conversion rate than CLS, with no 
differences in complication rate as surrogate markers of successful surgery.
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Real-woRld saFety aNd eFFiCaCy oF NAB-PaClitaxel iN PatieNts 
with metastatiC BReast CaNCeR (mBC) tReated iN the uNited states: 
Results FRom a health iNsuRaNCe dataBase
Patt D.1, Liang C.2, Li L.2, Ko A.3, Duval Fraser C.3, Corzo D.4, Enger C.5
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5Optum, Ann Arbor, MI, USA
although a variety of options were available on the market for 3rd-line mCRC treat-
ments, there is no conclusive evidence for an optimal choice in therapy. The difference 
in OS among chemotherapy backbones was not significant (log-rank test, p= 0.06), 
whether they were targeted therapies or not. Novel and newly approved treatments 
may provide further benefit for mCRC patients continuing on 3rd-line therapy.
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(NsClC) ReCeiviNg sequeNtial theRaPy
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Objectives: In recent years, the treatment landscape in nsNSCLC has changed; 
new therapies (e.g. bevacizumab (BEV) indicated in 1L) have become available and 
other therapies (e.g. pemetrexed (PEM) in 1L and 2L) moved into earlier lines in the 
treatment paradigm. While there has been an expansion of the available treat-
ment options, it is unclear how the therapy sequence rank in terms of best PFS 
for patients with nsNSCLC. MethOds: A therapy sequencing disease model that 
approximates treatment outcomes in up to five lines of treatment was developed 
for patients with nsNSCLC. The primary source of data for PFS and time to death 
was published pivotal trial data. All patients were treatment-naïve and in the 
PFS state, receive first-line treatment with either BEV-based therapy or doublet 
chemotherapy (including the option of pemetrexed + cisplatin (PEM+CIS)). Patients 
would then progress to a subsequent line therapy, remain in PFS or die. In case of 
progression, it was assumed that each survivor would receive a subsequent line 
of therapy (based on EMA licensed therapies). Weibull distribution curves were 
fitted to the data. Results: All BEV-based first-line therapy sequences analyzed 
achieved total PFS of more than 15 months. Bevacizumab-carboplatin-paclitaxel (1L) 
à pemetrexed (2L) à erlotinib (3L) à docetaxel (4L) resulted in total mean PFS time 
of 15.5 months, for instance. Sequences including PEM+CIS in first-line achieved 
total PFS times between 12.3 and 13.3 months with potentially (slightly) higher 
total PFS time achieved when assuming PEM continuation therapy in maintenance 
after PEM+CIS in 1L induction. cOnclusiOns: The model suggests that treatment 
sequencing strategies starting with a BEV-based combination in 1L yield better PFS 
outcomes than those starting with PEM-based combinations due to the possibility 
of one further-line treatment starting with BEV-based combination.
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a PhaRmaCoeCoNomiC aPPRaisal oF CaBazitaxel veRsus aBiRateRoNe 
FoR the seCoNd-liNe tReatmeNt oF PatieNts with metastatiC 
hoRmoNe-ReFRaCtoRy PRostate CaNCeR (mhRPC) PRogRessiNg aFteR the 
tReatmeNt with doCetaxel: a systematiC Review
Bektur C., Nurgozhin T.
Nazarbayev University, The Center for Life Sciences, Astana, Kazakhstan
Objectives: Currently,there are two drugs recommended by EAU for the second-
line treatment of mHRPC after docetaxel-based therapy:cabazitaxel and abiraterone 
acetate. The purpose of this study was to evaluate the available data on effective-
ness, safety and major pharmacoeconomic aspects of cabazitaxel and abiraterone 
for the treatment of patients with mHRPC progressing after the treatment with doc-
etaxel. MethOds: Relevant publications were identified using a predefined search 
strategy on major academic databases (MEDLINE, EMBASE, Cochrane Library) and 
conference proceedings. Articles and documents published in English and Russian 
languages between January2010 and December2013 were accepted for the full text 
evaluation. Data(study characteristics and end points/results) was extracted and 
summarized from eligible articles accepted according to the applied inclusion and 
exclusion criteria. Results: 63 articles were accepted for the full text evaluation 
from 331 identified abstracts from primary search of databases. 17 full-text publi-
cations were included in the data extraction after meeting the predefined criteria. 
59% of these publications were regarding the effectiveness and safety of drugs. The 
abiraterone treatment resulted in a higher median overall survival (15,8 months, 
95% CI, 14,8–17,0) than the therapy with cabazitaxel (15,1 months, 95% CI, 14,1–16,3). 
Moreover, median progression-free survival (median time to PSA progression) was 
8.5 (95% CI 8,3–11,1) and 2.8 (95% CI 2,4–3,0) months, respectively. Overall, abira-
terone has a better toxicity profile than cabazitaxel, the most common grade 3-4 
adverse effects for abiraterone was fatigue(9%) and anaemia(8%), and for cabazitaxel 
they were neutropenia(82%) and diarrhea(6%). Abiraterone was more cost-effective 
compared to placebo ($94 -123.4K/QALY) than cabazitaxel compared to placebo 
($149 - 163.2K/QALY), according to 4 identified articles with CEA. cOnclusiOns: 
The results of present review show that abiraterone is a more favourable option for 
the second-line treatment of patients with mHRPC progressing after the docetaxel-
based treatment than cabazitaxel in terms of safety and cost-effectiveness.
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the Relative CliNiCal aNd eCoNomiC value oF iPilimumaB as FiRst-
liNe tReatmeNt oF metastatiC melaNoma veRsus otheR aNti-CaNCeR 
ageNts FoR metastatiC diseases
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Objectives: Payers, patients, and clinical decision-makers expect value from 
innovative anti-cancer agents. Ipilimumab, an anti–CTLA-4 monoclonal antibody, 
has been shown to provide durable long-term survival for a proportion of unre-
sectable/metastatic melanoma patients, with follow-up in some out to 10 years; 
